EU approves J&J vaccine use… Secure the fourth vaccine

Input 2021.03.12 01:32 | Revision 2021.03.12 01:40

The European Union (EU) executive committee officially approved the conditional sale of a novel coronavirus infection (Corona 19) vaccine developed by global pharmaceutical company Johnson & Johnson (J&J) on the 11th (local time).

According to Reuters and others on the day, Ursula Fon der Leien, the EU Commissioner, said on his Twitter that “in accordance with the recommendations of the European Medicines Agency (EMA), the J&J vaccine has been approved for commercial use in the EU.

Earlier that day, EMA held a meeting of the Drug User Advisory Committee (CHMP) and recommended approval for conditional use of the J&J vaccine for those over 18 years of age.

The J&J vaccine is the fourth vaccine approved in the EU. Until now, vaccines developed by Pfizer, a US pharmaceutical company, Bioentech, Germany, Modena in the US, and AstraZeneca and Oxford University in the UK have been licensed.

The J&J vaccine has the advantage that it only needs to be vaccinated once, unlike other vaccines that require two doses. Because it can be stored at temperatures from 2 to 8 degrees Celsius, it is easier and cheaper to transport and store.

EMA explained that the vaccine had a 67% preventive effect in clinical trials, and the side effects were mild to moderate, disappearing after a few days of vaccination, and the most common symptoms were pain at the vaccination site, headache, fatigue, muscle pain, and nausea. .